resTORbio was a mTOR-pathway geroscience pioneer developing RTB101 to target age-related disease; after its lead Phase 3 trial failed, it reverse-merged into Adicet Bio in 2020 and abandoned its aging program.
Swiss aging-biotech (formerly Rejuveron) building a portfolio of therapeutics targeting the hallmarks of aging.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →